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Background. The arterial pharmacokinetics of ketamine and norketamine enantiomers after
racemic ketamine or S-ketamine i.v. administration were evaluated in seven gelding ponies in a
crossover study (2-month interval).
Methods. Anaesthesia was induced with isoflurane in oxygen via a face-mask and then main-
tained at each pony’s individual MAC. Racemic ketamine (2.2 mg kg21) or S-ketamine
(1.1 mg kg21) was injected in the right jugular vein. Blood samples were collected from the
right carotid artery before and at 1, 2, 4, 8, 16, 32, 64, and 128 min after ketamine adminis-
tration. Ketamine and norketamine enantiomer plasma concentrations were determined by
capillary electrophoresis. Individual R-ketamine and S-ketamine concentration vs time curves
were analysed by non-linear least square regression two-compartment model analysis using
PCNonlin. Plasma disposition curves for R-norketamine and S-norketamine were described by
estimating AUC, Cmax, and Tmax. Pulse rate (PR), respiratory rate (Rf ), tidal volume (VT),
minute volume ventilation (VE), end-tidal partial pressure of carbon dioxide (PE
0
CO2
), and mean
arterial blood pressure (MAP) were also evaluated.
Results. The pharmacokinetic parameters of S- and R-ketamine administered in the racemic
mixture or S-ketamine administered separately did not differ significantly. Statistically significant
higher AUC and Cmax were found for S-norketamine compared with R-norketamine in the
racemic group. Overall, Rf, VE, PE
0
CO2
, and MAP were significantly higher in the racemic group,
whereas PR was higher in the S-ketamine group.
Conclusions. Norketamine enantiomers showed different pharmacokinetic profiles after
single i.v. administration of racemic ketamine in ponies anaesthetised with isoflurane in oxygen
(1 MAC). Cardiopulmonary variables require further investigation.
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The rational use of ketamine, alone or in combination
with volatile anaesthetics, relies on the knowledge of its
disposition within the body, so that dose recommen-
dations can be established and adjusted according to the
desired blood or plasma drug levels. Although the dispo-
sition of ketamine is well documented in horses,1 – 4 only
one study reports the plasma levels of ketamine and
norketamine enantiomers obtained after racemic (R-/S-)
ketamine i.v. administration for anaesthesia induction in
this species.5 This study showed higher plasma levels of
S-norketamine than R-norketamine, suggesting that
N-demethylation might be highly enantioselective in
horses. The potential for discrimination between enantio-
mers at different stages of drug metabolism is therefore
# The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
British Journal of Anaesthesia 98 (2): 204–12 (2007)
doi:10.1093/bja/ael336 Advance Access publication January 11, 2007
important and highlights the need for stereospecific drug
assays.6
In humans and mice, the S-enantiomer has been proven
advantageous, reaching an identical depth of anaesthesia
with only half of the necessary racemic dose.7 – 9
Differences in the metabolism of the ketamine enantio-
mers after R-/S-ketamine administration when compared
with the sole S-ketamine administration might partially
explain the faster recovery of the psychomotor function
observed when S-ketamine is given alone.9 – 12
As a prelude to studying ketamine infusions in horses,
the main goal of this study was to determine the pharma-
cokinetic profile of ketamine enantiomers after a single
i.v. bolus of either R-/S-ketamine or S-ketamine in
healthy ponies under isoflurane anaesthesia.
Materials and methods
Study design and animals
The experiments were performed with permission of the
committee for animal experimentation, Bern, Switzerland.
The experimental trial was designed as a randomized pro-
spective 2-month interval cross-over study. Seven exper-
imental, 4 year-old, Shetland pony geldings, mean weight
122 kg (SD 16 kg), were included in this study. The ponies
were administered first R-/S-ketamine (RS-k) and after
2 months of wash-out interval, S-ketamine (S-k). They
were conventionally housed as a group at the equine clinic
of the Vetsuisse-Faculty (Bern, Switzerland). The animals
had their right carotid artery surgically elevated to allow
easy access by percutaneous puncture about 2 yr before
this experiment and were judged healthy on the basis of
physical examination, complete blood count and biochem-
istry profile. On the day before the experiment, ponies
were housed in a separate box to allow withholding of
food for 24 h. Access to water was granted until 1 h prior
to the study.
Anaesthesia and instrumentation
The whole animal experimental phase was conducted in a
padded recovery stall to both induce anaesthesia and
allow for a safe anaesthetic recovery. A broad rope to
restrain horses was placed around the ponies’ pectoralis
region, then passed around their hind quarters below their
quadriceps and anchored to itself over the left side of their
chest. After protective bandaging of the extremities, an
additional rope was placed around every metacarpus/
metatarsus. By pulling and stretching the ropes gently, the
ponies were smoothly placed in right lateral recumbency
and restrained in that position until anaesthesia induction
was achieved. Ponies were trained to be restrained with
this technique from prior studies.13 Anaesthesia was then
induced with isoflurane in oxygen (O2) via a hermetically
closed face mask connected to a small-animal anaesthesia
circle system (Roche Electronic Respirator 3100,
F. Hoffmann-La Roche, Basel, Switzerland). The vapori-
zer was first set to 1% and isoflurane delivery started via
the face mask (O2 flow: 6 litres min
21) and gradual incre-
ments of 0.5% were made over 5 min until the ponies
reached an appropriate anaesthetic plane for endotracheal
intubation (muscle relaxation, eyeball rotation, reduced pal-
pebral reflex, absence of swallowing reflex). Subsequently,
a 14 mm ID cuffed rubber–silicone tube was placed into
their tracheas and connected to the breathing system.
Ponies were let to breathe spontaneously throughout the
whole procedure. In the event of apnoea longer than 30 s,
intermittent positive pressure ventilation (IPPV) was
applied by manually squeezing the reservoir bag of the
breathing system twice per minute until spontaneous venti-
lation was restored. Anaesthesia was maintained with iso-
flurane in O2 throughout the whole experiment, at each
pony’s predetermined individual minimum alveolar con-
centration (iMAC). The iMAC for each pony [mean 0.97%
(SD 0.17%)] was determined in a previous study.13
The skin over the right jugular vein and the left carotid
artery was clipped and surgically prepared for percutaneous
placement of intravascular catheters. The right jugular vein
was catheterized with a 13-gauge catheter (Intranule PP,
Vygon, Ecouen, France), and Ringer’s lactate solution
10 ml kg21 h21 (RLS, Laboratorium Bichsel Baar,
Switzerland) was delivered intravenously throughout the
procedure with the aid of two volumetric infusion pumps
(Vet/IV 2.2 Heska, Ballerup, Denmark). The left carotid
artery was catheterized using a 20G/1.1045 mm arterial
catheter (B-D Arterial Cannula with FloSwitch, Ohmeda,
Swindon, UK). Later on, the jugular port served for test
drug administration and the arterial port served for blood
sampling and invasive blood pressure monitoring. To facili-
tate test drug administration or blood collection, three-way
stopcock valves were attached to the hubs of the venous
and arterial catheters between the RLS line and the invasive
blood pressure line, respectively.
Anaesthesia monitoring and physiological
data collection
A lead II electrocardiogram was displayed and haemo-
globin oxygen saturation (SpO2) was determined with a
pulse oximeter infrared probe placed on the tongue, which
also calculated the pulse rate (PR). Inspired and expired
O2 concentrations, end-expired isoflurane concentrations
(FE0 ISO), capnogram and end-tidal carbon dioxide partial
pressure (PE0CO2), tidal volume (VT), and minute volume
ventilation (VE) were obtained from a calibrated pitot tube
flow sensor and side-stream gas sampler probe (D-lite
Patient Spirometry TM, Datex-Ohmeda, Helsinki, Finland)
inserted between the endotracheal tube and the Y-piece of
the breathing system. Respiratory rate (Rf ) was calculated
from the capnogram. Mean arterial pressure (MAP) was
determined directly with a calibrated pressure transducer
(Angiokard, Medizintechnik GmbH & Co. KG, Friedeburg,
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Germany) from the catheter placed in the carotid artery.
The zero level in the transducer was set at the presumed
level of the heart base (point of shoulder). In addition, the
difference of the pharyngeo-oesophageal temperature
(dT8) between the initial value measured after endotracheal
intubation and the final value measured at the end of the
procedures was recorded. A portable anaesthesia monitor
(Datex S-5 portable anaesthesia monitor, Datex-Ohmeda,
Helsinki, Finland) continuously displayed the aforemen-
tioned data. The monitor was calibrated with a stan-
dardized calibration gas (DOT-34 NRC/375M1014,
Datex-Ohmeda, Helsinki, Finland) prior to each exper-
iment according to the manufacturers’ instructions. A
laptop computer connected to the monitor served to record
every 5 min the displayed data from 5 min before the test
drug administration (baseline data) and throughout the
sampling time. In addition, the need for IPPV was also
manually recorded. After complete recovery from anaes-
thesia, animals were returned to their boxes.
Drug administration and sample collection
Ponies were left to stabilize end-tidal isoflurane concen-
trations to their individual isoflurane MAC for about
20 min. A single i.v. dose of R-/S-ketamine (RS-k)
2.2 mg kg21 or S-ketamine (S-k) 1.1 mg kg21 were admi-
nistered intravenously. Five millilitres of arterial blood
were collected manually over 5 s into heparinized tubes
from the carotid artery catheter immediately before and at
1, 2, 4, 8, 16, 32, 64, 128 min after test drug injection. To
avoid contamination with the arterial flushing solution,
5 ml of blood was collected and discharged before every
sampling event. After the samples were obtained, the
arterial catheter was flushed with 10 ml of physiologic
saline solution. Immediately after collection, the samples
were placed on ice until centrifugation was performed
(maximum: 45 min) and plasma was frozen at 2808C
until the assay was performed.
Ketamine and norketamine enantiomer analysis
The plasma samples were analysed by enantioselective
capillary electrophoresis (CE) according to the technique
described by Theurillat and colleagues,14 and plasma con-
centrations for R-ketamine, S-ketamine, R-norketamine,
and S-norketamine were obtained. Briefly, this technique
is based on liquid–liquid extraction of ketamine and nor-
ketamine at alkaline pH from 1 ml plasma followed by
analysis of the reconstituted extract by CE in the presence
of a pH 2.5 Tris–phosphate buffer containing highly sul-
fated b-cyclodextrin 10 mg ml21 (Sigma Aldrich Chemie,
Schnelldorf, Germany) as chiral selector. Analyses were
performed on the P/ACE MDQ Capillary Electrophoresis
Analyzer (Beckman Coulter, Fullerton, CA, USA) using a
50 mm ID fused-silica capillary of 28 cm effective length,
an applied voltage of 220 kV and a cartridge temperature
of 308C. The detection wavelength was 195 nm. The limit
of detection for all enantiomers was 0.01 mg ml21 and
intraday and interday precisions (n¼5) were ,8% and
,14%, respectively.
Pharmacokinetic analysis
R-ketamine and S-ketamine concentration vs time curves
were analysed for each individual by non-linear least
square regression two-compartment model analysis using
PCNonlin (SCI Software, Lexington, USA). Plasma con-
centration obtained after i.v. administration was fitted to a
polyexponential equation:
CðtÞ ¼
X
i
Yie
lit
where C(t) (mg ml
21) is the plasma concentration at time t;
Yi (mg ml
21) is the coefficient of the ith term, and li (per
hour) is its exponent. Initial estimates were determined
using the residual method15 and refitted by non-linear
regression analysis. The number of exponents needed were
determined by applying the Schwartz16 and Akaike cri-
teria.17 Most pharmacokinetic parameters were calculated
using classic equations associated with compartmental
analysis. Distribution and elimination half-lives (t1/2alpha
and t1/2beta, respectively) were calculated as t1/2
alpha¼0.693/l1 and t1/2beta¼0.693/l2. Area under the
plasma concentration–time curve (AUC(021)) and mean
residence time (MRT, measure of drug elimination
expressed as the average time a drug molecule remains in
the body after i.v. injection) were calculated by the trape-
zoidal rule with extrapolation to infinity. The extrapolated
area was estimated as AUC(Clast21)¼Clast/l2, where Clast is
the last measured concentration. Body clearance (ClB) was
determined as ClB¼dose/AUC(021) and the steady-state
volume of distribution (V(d(ss))) was calculated as
V(d(ss))¼ClBMRT. Plasma disposition curves for
R-norketamine and S-norketamine were described by esti-
mating AUC, Cmax, and Tmax.
Statistical methods
The NCSS 2004 (Kaysville, UT, USA) and the SigmaStat
3.1 (Point Richmond, CA, USA) software packages were
used to perform the statistical evaluation. All data were
analysed for normal distribution with the Martinez–Iglewicz
test. The significance of difference between groups for dT8,
ketamine, and norketamine enantiomers plasma levels and
the estimated pharmacokinetic parameters was assessed with
the Wilcoxon signed rank test or, when applicable, the
Student’s paired t-test. Each animal served as its own match.
For PR, MAP, PE0CO2, Rf, and VE, a statistical comparison
was made between SR-k and S-k treatment groups before
and after test drug administration using an analysis of
variance test and for VT using a two-way analysis on ranks
Friedman test. For all tests, overall P,0.05 was considered
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the minimum level of statistical significance. Parametric data
are presented as mean (SD) and non-parametric data are
presented as median and range.
Results
Anaesthesia
The overall induction, maintenance, and recovery from the
anaesthetic episodes were uneventful. In one pony, the
administration of the S-ketamine and the RLS infusions
were performed via a 16-gauge catheter placed in the right
cephalic vein because of obstruction of the left jugular
vein catheter. Differences between treatment groups in dT8
were not statistically significant [RS-k: 0.6 (0.4)8C; S-k:
0.9 (0.6)8C].
Cardiopulmonary data
There were no statistically significant differences in the
cardiopulmonary variables between groups during the
baseline measurements. Trends for PR are presented in
Figure 1. Ponies in the RS-k treatment group had signifi-
cantly lower (P,0.001) overall PR compared with the S-k
treatment group (Fig. 1). Trends for MAP are presented in
Figure 2. Overall MAP values where higher (P¼0.006) in
the RS-k when compared with the S-k group. Trends for
PE0CO2, VE, and Rf are presented in Figure 3. Ponies in the
S-k treatment group had a significantly lower (P,0.001)
PE0CO2 compared with the RS-k treatment group (Fig. 3A).
The VE was significantly higher (P,0.001) in the RS-k
treatment group than in the S-k treatment group (Fig. 3B).
Overall Rf values were higher (P,0.001) in the RS-k treat-
ment group than the S-k treatment group (Fig. 3C).
Immediately after both test drug administrations, three of
seven ponies in each group developed apnoea longer than
30 s. After applying IPPV for 1–2 min all of them restored
to spontaneous respiration. Differences in VT were not stat-
istically significant between treatment groups (RS-k group,
median: 1.04 litre, range: 0.24–2.61 litre; S-k group,
median: 0.99 litre, range: 0.05–3.06 litre). VT decreased
in both groups after test drug administration and restored
to baseline values at 10 min. Mean SpO2 for the entire
anaesthetic episode was 99 (0.9)% in the RS-k treatment
group and 98.8 (0.4)% in the S-k treatment group.
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Fig 1 Mean and SD of PR plotted over time after R-/S-ketamine and
S-ketamine administration to seven ponies anaesthetized with isoflurane
in oxygen. The arrow marks the time of drug injection.
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Fig 3 Mean and SD of PE0CO2 (A), VE (B), and Rf (C) plotted over time
after R-/S-ketamine and S-ketamine administration to seven ponies
anaesthetized with isoflurane in oxygen. The arrow marks the time of
drug injection.
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Fig 2 Mean and SD of MAP plotted over time after R-/S-ketamine and
S-ketamine administration to seven ponies anaesthetized with isoflurane
in oxygen. The arrow marks the time of drug injection.
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Plasma concentrations of ketamine and
norketamine enantiomers
A total of 126 plasma samples (RS-k¼63, S-k¼63) were
analysed by CE and used for the concentration–time data
evaluation. R-ketamine and R-norketamine were not
detected after administration of S-ketamine. Trends for
ketamine and norketamine plasma concentrations are pre-
sented in Figures 4 and 5. S-ketamine plasma concen-
trations were statistically significantly lower (P¼0.03) in
the S-k treatment group than in the RS-k treatment group
at 2 min (Figs 4A and 5A). At the same time point,
S-ketamine plasma concentrations were statistically signifi-
cantly lower (P¼0.005) when compared with the
R-ketamine plasma concentrations in the RS-k treatment
group (Fig. 4A). No other significant differences were
determined. Plasma concentrations for S-norketamine were
statistically significantly higher than plasma concentrations
of R-norketamine in the RS-k group at 2 (P¼0.005), 8
(P¼0.007), 16 (P¼0.01), 32 (P¼0.005), 64 (P¼0.008),
and 128 (P¼0.03) min. No statistical difference was noted
at 1 (P¼0.297) and 4 (P¼0.147) min. The plasma concen-
trations of the S-norketamine in the S-k group were
similar to its homologous enantiomer in the RS-k group
(P.0.05 for all time points, Figs 4B and 5B).
Pharmacokinetic analysis
The pharmacokinetics for all ketamine enantiomers could
be well described with a two-compartment model. No sig-
nificant differences in the pharmacokinetic variables
between and within treatment groups could be detected for
the ketamine enantiomers. The AUC and Cmax of
R-norketamine were found to be significantly smaller
(P¼0.002 and P¼0.009, respectively) than those of
S-norketamine in the RS-k treatment group. No other sig-
nificant differences could be determined. Table 1 summar-
izes the results of the population analysis for all
compounds.
Discussion
In the present study, the pharmacokinetic parameters of
R- and S-ketamine after single i.v. injection of the race-
mate or the single S-enantiomer in ponies under isoflurane
anaesthesia, did not significantly differ. The statistically
significant differences found for the S-ketamine plasma
concentrations 2 min after administration of either R-/S-
or S-ketamine had no significant impact on the calculated
pharmacokinetic variables. However, the statistically sig-
nificant differences found in the plasma disposition of S-
and R-norketamine after administration of the racemate,
mirrored by their calculated pharmacokinetic parameters,
suggest that in ponies anaesthetized with 1 iMAC isoflur-
ane, the metabolism of racemic ketamine is highly
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Fig 4 Mean and SD of plasma concentrations of (A) S-ketamine and
R-ketamine and (B) S-norketamine and R-norketamine after R-/
S-ketamine administration to seven ponies anaesthetized with isoflurane
in oxygen. *P,0.05 within treatment group. **P,0.05 between the two
treatment groups (comparison with data of Fig. 5A).
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Fig 5 Mean (SD) plasma concentrations of (A) S-ketamine and (B)
S-norketamine after S-ketamine administration to seven ponies
anaesthetized with isoflurane in oxygen. **P,0.05 between treatment
groups (comparison with data of Fig. 4A).
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stereoselective. In both treatment groups, the arterial
plasma concentrations of ketamine enantiomers followed a
biexponential decline, with a rapid initial distribution
phase being followed by a slower elimination phase. This
profile was analogous to those previously published
for humans,11 dogs,18 and cross-bred horses.5 Similar to
humans and most other species,1 2 4 5 10 18–21 high variabi-
lity among individuals was observed in the plasma con-
centrations of ketamine and norketamine. Former studies on
the pharmacokinetics of S-/R-ketamine in horses reported
data analysed from venous samples.1–5 In isoflurane anaes-
thetized ponies, large differences (up to 50%) were found
between arterial and venous pharmacokinetics of ketamine
isomers caused by both, distribution and elimination pro-
cesses.22 In situations in which potent short-acting drugs are
used, such as anaesthetics, these differences can be of con-
siderable importance.23 Because the drug concentrations at
the target organ are probably more closely related to arterial
than to venous concentration, the controlling parameters
should be based on arterial rather than venous data.10 24 The
present study is the first investigating the arterial
stereoselective pharmacokinetic profile of S-/R-ketamine
compared with S-ketamine in an equine species.
The iMAC is the midpoint of two end-tidal anaesthetic
concentrations that just permit or just prevent gross purpose-
ful movement after applying a supramaximal stimulation
in a single anaesthetized individual.25 Individual MAC
values are normally averaged to obtain the MAC in a
group of subjects. The use of each pony iMAC, instead of
the MAC of the group, aimed to have a comparable degree
of immobility among test animals. I.V. R-/S-ketamine at a
dose of 2.2 mg kg21 is well documented to induce anaes-
thesia in sedated horses.2 4 Such doses, however, are seldom
administered in clinical practice to horses already receiv-
ing 1 MAC of isoflurane. This dose was chosen delibera-
tely to create a basis for further studies on constant rate
infusion of ketamine in isoflurane-anaesthetized horses.
As a racemate has equal proportions of each enantiomer,
a dose of 1.1 mg kg21 of S-ketamine was chosen to
compare the profiles of the S-enantiomer in both treatment
groups.
Previous investigations in rats21 and dogs26 anaesthe-
tized with halogenated agents showed alterations in organ
perfusion, which in turn slowed down uptake, distribution,
and redistribution of ketamine. Thus, an increased appar-
ent volume of the central compartment (Vc) could be
expected, probably because of a slower elimination of the
compounds by poorly perfused organs of elimination. It
has long been suggested that distribution of drugs may be
not only affected by blood flow but also by active transport
across the endothelium.27 It was postulated that the
binding affinity of the chiral forms of ketamine to mem-
brane receptors responsible for protein-mediated transport
across the vascular endothelium might exhibit stereospeci-
ficity, showing different distribution profiles between enan-
tiomers. However, several authors failed to demonstrate
ketamine distribution to be stereoselective in humans10 11 28
and in dogs.18 Similarly, in the present study, the half-lives
and the Vc for the ketamine enantiomers did not differ
significantly between and within groups, suggesting that
ketamine distribution is not enantioselective in the equine
species either.
MRT and ClB values calculated from the arterial plasma
ketamine concentrations determined after S-ketamine or
R-/S-ketamine i.v. administration were similar for all
enantiomers. Studies conducted in humans showed a
significantly higher ClB for S-ketamine compared with
R-ketamine after administration of either enantiomer.11 28 29
Ihmsen and colleagues10 showed a higher S-ketamine body
clearance in men when the drug was administered as an
infusion of the pure enantiomer compared with an infusion
of the racemate. In contrast, Yanagihara and colleagues30
showed no differences between the pharmacokinetics of
ketamine enantiomers and this dissimilarity was attributed to
variability related to human races. Inter-individual variations
between comparison groups, differences in the sampling site
(arterial vs venous), or both might also account for such
discrepancies.10
Several factors seem to have an important impact on the
metabolism of the ketamine isoforms. Ketamine is rapidly
and extensively metabolized by the hepatic microsomal
cytochrome P450 enzymes to norketamine, hydroxynorke-
tamine, hydroxyketamine, and dehydronorketamine.31 – 35
Table 1 Mean (SD) of pharmacokinetic parameters of arterial plasma S- and
R-ketamine obtained from ponies (n¼7) anaesthetized with isoflurane in
oxygen after i.v. R-/S-ketamine (2.2 mg kg21) or S-ketamine (1.1 mg kg21)
administration. *P,0.05 between enantiomers within the R-/S-ketamine
treatment group. A, distributive exponential phase; B, terminal exponential
phase; Alpha, hybrid rate constant of biphasic i.v. disposition curve
(distribution phase); Beta, hybrid rate constant of biphasic i.v. disposition
curve (elimination phase); K10, first-order elimination rate constant; K12 and
K21, first-order transfer rates between central and peripheral compartments;
Cmax, maximum observed concentration value; Tmax, time point at which Cmax
occurs
S-ketamine R-/S-ketamine
S-ketamine R-ketamine
A (mg ml21) 9.7 (14) 5.6 (2) 5.4 (1.6)
B (mg ml21) 0.7 (0.6) 0.4 (0.1) 0.5 (0.3)
Alpha (min21) 0.7 (0.5) 0.4 (0.08) 0.4 (0.1)
Beta (min21) 0.05 (0.05) 0.03 (0.01) 0.03 (0.01)
AUC (mg min ml21) 29.1 (18.1) 27.1 (6.34) 26.8 (5.3)
t1/2alpha (min) 1.4 (0.8) 1.6 (0.3) 1.7 (0.3)
t1/2beta (min) 26 (22.5) 23.6 (8.1) 24.2 (7.4)
K10 (min21) 0.3 (0.2) 0.2 (0.05) 0.2 (0.05)
K12 (min21) 0.3 (0.2) 0.1 (0.05) 0.2 (0.1)
K21 (min21) 0.1 (0.1) 0.06 (0.02) 0.07 (0.04)
Vc (litre kg
21) 0.2 (0.1) 0.2 (0.06) 0.2 (0.1)
ClB (litre kg
21 min21) 0.05 (0.02) 0.04 (0.01) 0.04 (0.01)
MRT (min) 24.6 (24.1) 18.9 (6.2) 19.1 (5.7)
V(d(ss)) (litre kg
21) 0.9 (0.8) 0.8 (0.3) 0.8 (0.3)
S-norketamine S-norketamine R-norketamine
AUC (mg min ml21) 14.8 (0.5) 17.8 (6.4)* 10.4 (3)*
Cmax (mg ml
21) 0.48 (0.2) 0.5 (0.08)* 0.4 (0.06)*
Tmax (min) 3.6 (2.3) 7.1 (4.5) 4.3 (1.8)
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In vitro studies revealed that N-demethylation of
S-ketamine by human liver microsomes is 20% larger than
that of R-ketamine and 10% greater when compared with
the racemic compound.36 Two enzymes with stereospecific
preference for one enantiomer over the other, or four
enzymes with different stereospecific substrate activities
and different metabolic rates might account for this
enantioselective N-demethylation.36 In contrast another
in vitro study with human liver microsomes suggested
a non-enantioselective N-demethylation of R- and
S-ketamine.37
The comparable values obtained for the calculated phar-
macokinetic variables of the S-isoforms of ketamine and
norketamine in both groups suggest no interference of the
R-enantiomer with the overall elimination of the
S-enantiomer in the racemate. However, the significant
differences found for the R- and S-norketamine in the
RS-k treatment group suggest that some differences exist
with regard to their particular metabolic pathways. This
finding corresponds with data in which similar results
were obtained after a single dose of S- or R-/S-ketamine
administration to human patients11 and horses.5 In the
latter study, a S/R ratio for norketamine of 75:25 immedi-
ately after and 90:10 40 min after i.v. administration of
R-/S-ketamine (6 mg kg21) was reported. The authors
postulated that these ratios could be the consequence of
substrate enantioselectivity of the cytochrome-dependent
N-demethylation. In the present study, an enzyme–
substrate competition seems unlikely because similar ClB
rates were found for the S-enantiomer in both groups
suggesting the presence of other enantioselective processes
involved in the elimination of ketamine. Norketamine is a
pharmacologically active metabolite and was found to
have a potency of around 30% of that of the parent drug.38
The hydroxylated metabolite 6-hydroxynorketamine has
been reported to be a weaker anaesthetic and to produce
less post-anaesthetic excitation than norketamine.39
Consequently, norketamine elimination pathways might
have a relevant influence on the overall ketamine activity.
Interestingly, the hydroxylation of norketamine also
exhibited enantioselectivity at different positions on the
cyclohexanone ring.35 Therefore, it could be possible that
in the present study, R-norketamine hydroxylation may
have prevailed, accounting for the lower plasma concen-
trations reflected into the lower AUC and Cmax observed
for that metabolite. Unfortunately, we were unable to
quantify the plasma concentrations of the hydroxylated
forms of norketamine to test this hypothesis.
Renal excretion seems to play a significant role in nor-
ketamine elimination in horses.40 Differences in plasma
protein binding leading to different renal clearance may be
expected for chiral compounds.41 Therefore, different renal
clearance rates for norketamine enantiomers could also
explain the higher concentrations obtained for
S-norketamine in ponies’ plasma when compared with
those of R-norketamine. Kaka and colleagues4 proposed
involvement of extrahepatic pathways in the ketamine
metabolism in horses because the ketamine ClB exceeded
the calculated hepatic plasma flow rate. Studies performed
in rats reported extrahepatic inversion of R to S-ketamine
with subsequent metabolism to S-norketamine.42 In the
present study, no R-ketamine was detected after adminis-
tration of the pure S-enantiomer, and after administration
of the racemate, the mean plasma concentrations of R- and
S-ketamine were similar, suggesting no inversion between
the R- and S-enantiomers. Geisslinger and colleagues11
proposed that a possible inversion from R- to S-ketamine
could be masked by different stereoselective ClB rates,
resulting also in similar concentration profiles for both
enantiomers. However, the ClB of the R- and S-ketamine
were similar in our study.
Although the study reported here was mainly designed
to evaluate the pharmacokinetics of ketamine and norketa-
mine enantiomers, some cardiopulmonary data were also
collected. Generally, low doses of R-/S-ketamine are
known to increase heart rate and MAP as a consequence
of direct sympathetic stimulation.43 The reduction in MAP
observed for both compounds in the first 10 min after drug
administration could have been the result of direct central
nervous system depression in response to the high doses
used here. S-ketamine seemed to have produced a stronger
cardiac stimulation as evaluated by higher PR values
observed for the S-k group compared with the RS-k group.
In vitro studies showed an inhibition of the uptake of nor-
adrenaline at adrenergic neuronal endings by ketamine,
which occurred pre-synaptically with both enantiomers but
also post-synaptically with the S-isoform.44 On the other
hand, overall mean MAP values remained significantly
lower over time in the S-k treatment group compared with
the racemate. The reduced MAP values observed in the
S-k treatment group could have induced an autonomic
reflex response that increased the heart rate and vice versa
for the RS-k treatment group. Contrary to these findings,
Filzek and colleagues45 reported significantly lower heart
rate and higher MAP values in horses anaesthetized with
S-ketamine compared with those receiving R-/S-ketamine.
In man, several studies compared R-/S-ketamine with
S-ketamine and found equivalent cardiovascular stimula-
tion.10 46 47 Immediately after test drug administration and
for about 10 min, respiratory depression occurred (apnoea,
decreases in Rf, VT, and VE). A progressive increase in VE
was observed in both groups as test drugs were cleared from
plasma. Increases in Rf might have accounted for the overall
increases in the mean VE values observed in the RS-k treat-
ment group since VT remained similar between groups. In
turn, an overall increase in the arterial partial pressure of
carbon dioxide, reflected as an increase in the overall mean
PE0CO2 values in the RS-k treatment group, could have stimu-
lated the respiratory system via chemoreceptor activity result-
ing in the observed increases in VE and Rf. Alternatively,
increases in physiologic dead space could explain the lower
PE0CO2 values observed in the S-k treatment group.
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In conclusion, the disposition of racemic ketamine in
ponies anaesthetized with 1 iMAC isoflurane is stereo-
selective, leading to higher plasma concentrations of
S-norketamine. Several factors seem to influence the
metabolism of the ketamine isoforms. Further studies are
required to assess the impact of different dose regimes,
drug combinations, or both on the overall metabolism of
the enantiomers of ketamine. Under the conditions
reported here, administration of S-ketamine produced
different cardiopulmonary effects than those observed with
R-/S-ketamine. The underlying mechanisms responsible
for these differences remain to be elucidated.
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